display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HER2-positivebreast cancer - HR positive
la/mBC - HER2 positive - 1st Line (L1)la/mBC - HR-positive - 1st line (L1)
VEGF(R) inhibitor
bevacizumab based treatment
bevacizumab plus trastuzumab plus docetaxel AVEREL
cediranib plus fulvestrant NCT00454805

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons